12 results about "Pioglitazone" patented technology

The present invention is directed to a combination therapy involving Pioglitazone and a MEK inhibitor for the treatment of a cancer patient in need of such a therapy.

To provide a pharmaceutical composition for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).SOLUTION: Provided is a pharmaceutical composition comprising a. ibutamoren, b. pioglitazone, and c. a pharmaceutically acceptable carrier.SELECTED DRAWING: None

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an endocrine drug-derived anti-cancer composition as well as a preparation method and application thereof. The composition comprises a composite solid dispersion composed of an endocrine disease treatment drug metformin, pioglitazone or sitagliptin, a hydrophilic carrier material and a pretreated functional ion exchange resin. The preparation method mainly comprises the following steps: carrying out alkaline swelling and surface modification pretreatment on ion exchange resin, forming a uniform compound from the medicine, the carrier and the resin through a melting-adsorption-curing process, and carrying out nanocrystallization treatment and structure stabilization drying to obtain the nano composite powder. The composition can be used for preparing an oral solid preparation for inhibiting breast cancer, prostatic cancer, endometrial cancer or colorectal cancer, and has the potential advantage of improving drug dissolution and release behaviors by utilizing a composite structure; the preparation method can effectively guarantee the structural integrity and the performance consistency of the preparation, and the operation controllability is high.

1. Name of the design product: packaging box (metformin hydrochloride and pioglitazone hydrochloride tablet). 2. Use of the design product: the design product is used for the packaging of medicines. 3. Design points of the design product: the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.

The present invention is directed to a combination therapy involving Pioglitazone and a MEK inhibitor for the treatment of a cancer patient in need of such a therapy.

Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.

The utility model discloses a granulating device for producing pioglitazone and metformin tablets, and relates to the technical field of medicine production. A top cover is clamped to the top of the raw material box, a first rotating motor is fixedly clamped to the top of the top cover, lifting air cylinders are arranged on the periphery of the bottom of the raw material box, a granulation pressing plate is arranged in the center of the bottom of the raw material box, a cutting knife is slidably clamped to the bottom of the granulation pressing plate, and the net-shaped conveying belt is arranged at the bottom of the raw material box. By arranging the raw material box and the net-shaped conveying belt, the problems that when a cutting knife is used for directly cutting particles, due to the fact that metformin raw materials are high in humidity and viscosity, when the cutting knife is used for directly cutting the particles, a large number of particles are likely to be stacked and bonded and are inconvenient to dry subsequently, and when the cutting knife is too slow, the particles are likely to be attached to the surface of the cutting knife, and the cutting efficiency is poor are solved. And when particles of different sizes need to be extruded, an extrusion plate needs to be replaced, and time and labor are wasted in operation.

The present invention relates to a method for continuously preparing a pioglitazone intermediate in a microtubule reactor. The method uses 5-ethyl-2-(2-hydroxyethyl)pyridine as a starting material, and continuously reacts in a microtubule reactor through nucleophilic substitution and Knoevenagel condensation to prepare a pioglitazone intermediate 5-[[4-[2-(5-ethyl-2-pyridyl)-ethoxy]phenyl]methylene]-2,4-thiazolidinedione. The method has the advantages of enhanced mass transfer and heat transfer, overcomes the problems of inconvenient operation, low degree of automation, and high energy consumption cost in traditional intermittent reactor processes, significantly shortens the production cycle, improves the total yield, and is suitable for industrialized scale-up production.

The invention relates to a pioglitazone transdermal patch as well as a preparation method and application thereof. The transdermal patch comprises a backing layer and a drug reservoir layer, the drug reservoir layer comprises an active drug, a first solubilizer, a second solubilizer, a penetration enhancer and an adhesive, the active drug is pioglitazone or a pharmaceutically acceptable salt thereof, the first solubilizer is ethanolamine, the second solubilizer is sodium alginate, and the penetration enhancer is sodium alginate. The second solubilizer is selected from the group consisting of propylene glycol, ethanol, methanol, dimethyl sulfoxide, N-methyl pyrrolidone, acetone, and polyethylene glycol having a number average molecular weight of 200 to 8000. The transdermal patch can obviously reduce the fluctuation of blood concentration, and is beneficial to reducing the risk of toxic and side effects; and the long drug action time can be maintained, the administration frequency is reduced, and the patient compliance is improved.

The invention discloses application of a Hubei chloranthus spicatus sesquiterpene dimer compound in preparation of a medicine for treating a non-alcoholic fatty liver disease. The structural formula of the sesquiterpene dimer compound is shown as a formula (I). The invention finds that the compound has the effects of reducing liver cell lipid accumulation and improving the non-alcoholic fatty liver disease for the first time. And compared with pioglitazone recommended by international guidelines, the compound has the advantages of better non-alcoholic fatty liver disease resistance drug effect and lower toxicity. # imgabs0 #

The application belongs to the technical field of medicine, and particularly relates to application of pioglitazone combined with ligustilide in prevention and treatment of metabolic related fatty liver fibrosis. Specifically, the application first evaluates the protective effect of ligustilide alone in the liver fibrosis caused by high-fat and high-sugar stimulation in vivo and in vitro. Meanwhile, in the evaluation process of improving related liver fibrosis damage of the pioglitazone and ligustilide drug combination, the high-fat and high-sugar model closely related to glucose and lipid metabolism disorder is innovatively constructed and selected. It is found that the curative effect of the combination of pioglitazone and ligustilide is significantly better than that of any one of the drugs used alone, and the combination exhibits a strong synergistic effect in inhibiting lipid synthesis, promoting lipid metabolism, regulating glucose metabolism and the like, so that a more effective and innovative prevention and treatment method is provided for clinical treatment of metabolic related fatty liver fibrosis, and therefore has important clinical significance and social benefits.

According to the fluorescent probe disclosed by the invention, the response to the pH is realized through intramolecular cyclization and ring opening mechanisms, and the response to the pH is reversible. Under the condition of pH triggering, the fluorescent probe LD-Nu-APP can dye the lipid droplets and the nucleolus and emit green fluorescence and red fluorescence respectively. The advantages of two-parameter detection (lipid content and nucleolus size) of the fluorescent probe LD-Nu-APP are utilized, the non-alcoholic fatty liver tissue and the normal tissue can be successfully distinguished, and the method is more accurate than Nile red which only depends on lipid change. Besides, based on the Bayesian theorem, the fluorescent probe LD-Nu-APP is used for screening and evaluating the two drugs for treating the non-alcoholic fatty liver disease, and it is found that pioglitazone is more effective than metformin, and the application range is wider. In conclusion, it is believed that the fluorescent probe LD-Nu-APP has unique lipid content-nucleolus size two-parameter detection characteristics and has huge value in non-alcoholic fatty liver disease diagnosis and drug screening.